Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial.
Ruth M de TuteCurly T C M MorrisDavid A CairnsJulia M BrownJamie CavenaghA John AshcroftJohn A SnowdenKwee YongEleni TholouliMatthew JennerAnna HockadayMark T DraysonTreen C M MorrisAndy C RawstronRoger G OwenPublished in: Bone marrow transplantation (2024)
Keyphrases
- stem cell transplantation
- multiple myeloma
- high dose
- newly diagnosed
- phase iii
- study protocol
- acute lymphoblastic leukemia
- bone marrow
- clinical trial
- acute myeloid leukemia
- phase ii
- cell therapy
- hodgkin lymphoma
- diffuse large b cell lymphoma
- platelet rich plasma
- low dose
- mesenchymal stem cells
- open label
- placebo controlled